APsense

Acute coronary syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments

The Acute coronary syndrome pipeline therapeutics pipeline is expected to increase on account of increasing population, which are at risk of severe cardiovascular disease. High blood pressure, uncontrollable blood sugar level, hypercholesterolemia, smoking are the main causes of developing acute coronary syndrome.



Sometimes, stroke, emotional trauma also make a platform for emerging abnormalities in cardiovascular system. Amendments in lifestyle, routine and habit makes a big difference for increasing continuum of cardiovascular disease. Cumulative growth of pipeline is expected to grow as long as the arena of morbidities due to cardiovascular disease is occurring. In 2009, around 18% of men and 23% of women in United States were at risk of myocardial infarction, accordingly American Heart Association. Increasing the hospital therapy cost also a floating factor for expanding pipeline growth of acute coronary syndrome because it is a make-up of many diseases like myocardial ischemia, unstable angina, myocardial infarction etc.


In June 2015, Sun Pharmaceutical Industries Ltd. and AstraZeneca Pharma India Limited (AZPIL) have entered into a distribution services agreement in India for AstraZeneca’s brand “Axcer”, a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark “Brilinta”, for ticagrelor molecule, which was launched and marketed by AZPIL in India since 2012.


Some of the companies having a pipeline of acute coronary syndrome therapeutics include, Roche Molecular Systems, Inc, MedImmune, LLC, AstraZeneca Plc, SIS Medical AG, Asklepion Pharmaceuticals, LLC, Genentech, Inc., GlaxoSmithKline plc.
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Share:

No comments:

Post a Comment

Popular Posts

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages